Target intelligence, structured and scored
Synapse reads thousands of papers and cross-references 20+ public databases to build evidence-scored target dossiers. Every claim scored. Every data point traced to source.
Your target at a glance
Every dossier opens with a structured executive summary: total evidence volume, top indications, modality precedent, safety alerts, and translational maturity, all on one screen.
No digging through papers. No assembling spreadsheets. The summary synthesizes what would take a team weeks into a single, reviewable view.
251 papers, 1,301 evidence items, 317 clinical trials, all structured and scored for GLP1R
Top indications: Hypertension, Coronary Artery Disease, Obesity +17 more
2 class liabilities: CNS GI
Scored disease associations
Every target-disease link is scored from 0 to 1.0 based on evidence strength across literature, clinical trials, and databases. Not a list of associations: a ranked, quantified assessment.
GLP1R shows strong signals across metabolic and cardiovascular indications, with emerging evidence in neuropsychiatric domains.
Enables evidence-based indication prioritization: compare signals across therapeutic areas at a glance
+5 more associations
Evidence maturity at every stage
See how evidence distributes across the translational spectrum: basic research, preclinical studies, and clinical trials. Gaps in the chain reveal where validation is missing.
GLP1R shows a complete translational chain: evidence spans all stages with no gaps, a strong signal of clinical readiness.
Translational gaps are the #1 predictor of late-stage failure. Synapse makes them visible upfront.
✓ Complete translational chain: no stage gaps detected
Where the literature disagrees
Synapse doesn't just aggregate: it detects contradictions. When studies report conflicting findings about a target-disease or target-protein link, a concordance score flags the disagreement.
GLP1R shows two active contradictions: the AP2M1 molecular interaction and the Coronary Artery Disease association, both below the 0.5 threshold.
No other platform actively flags contradictions. This is where confident decisions separate from assumptions.
Concordance Score · lower = more conflict
Scores below 0.5 indicate conflicting evidence requiring manual review.
Risk signals before they become failures
Every dossier includes a structured safety assessment: class liabilities, tissue expression patterns, and known adverse effects extracted from literature and trial data.
A single overlooked safety signal can kill a billion-dollar program. Synapse surfaces them early, with evidence links for every flag.
Safety-first by design: liabilities are surfaced in the executive summary, not buried in an appendix.
Class Liabilities
Central nervous system effects reported across 3 compound classes
Gastrointestinal adverse events, dose-dependent nausea profile
Tissue Expression
The competitive landscape, structured
Every drug that touches your target, organized by mechanism, development phase, and modality. See approved GLP-1 agonists alongside oral small-molecule candidates still in trials.
Tirzepatide's dual GIP/GLP-1 mechanism, Orforglipron's oral delivery: the strategic context for your program, not just a list of compounds.
309 drug interactions mapped: approved therapies, clinical candidates, and emerging modalities in one view
| Drug | Mechanism | Phase | Modality | Indication |
|---|---|---|---|---|
| Semaglutide | GLP-1 receptor agonist | Approved | Peptide | T2D, Obesity |
| Liraglutide | GLP-1 receptor agonist | Approved | Peptide | T2D, Obesity |
| Dulaglutide | GLP-1 receptor agonist | Approved | Fc-peptide | T2D |
| Exenatide | GLP-1 receptor agonist | Approved | Peptide | T2D |
| Tirzepatide | GIP/GLP-1 dual agonist | Approved | Peptide | T2D, Obesity |
| Orforglipron | Oral GLP-1 agonist | Phase 3 | Small molecule | T2D, Obesity |
| Danuglipron | Oral GLP-1 agonist | Phase 2 | Small molecule | T2D |
| Survodutide | GLP-1/Glucagon dual | Phase 3 | Peptide | NASH, Obesity |
+301 more interactions
See how your target connects
GLP1R doesn't act alone. Its signaling cascade runs through G-proteins (GNAS), arrestins (ARRB1/2), and downstream effectors (CREB1, MTOR), each a potential co-target or liability.
The network is interactive: hover any node to highlight its connections, drag to rearrange, zoom to explore. Physical interactions, signaling cascades, and functional links are color-coded.
228 protein-protein interaction partners: drag, zoom, and explore the network
Three targets. Three therapeutic areas. One framework.
Synapse applies the same structured analysis across any target. Compare evidence profiles side-by-side: metabolic, oncology, immunology.
| Target | Area | Papers | Trials | Drugs | Modalities | Translational |
|---|---|---|---|---|---|---|
| GLP1R | Metabolic | 251 | 317 | 309 | SM | Complete |
| EGFR | Oncology | 161 | 2,293 | 221 | SM, Ab, PROTAC, Other | Complete (4 gaps) |
| IL13 | Allergy | 60 | 73 | 20 | Ab (preferred) | Clinical focus |
17 sections. One dossier.
Every section structured, scored, and traced to source.
Drug Interactions
Known drugs, mechanisms, binding profiles, and competitive landscape
Indications
Scored disease associations with evidence strength
Clinical Development
Trial landscape by phase, indication, and status
Safety Profile
Class liabilities, tissue expression, adverse effects
Disease Associations
Full disease-target evidence map
Molecular Interactions
Protein-protein interaction network
Biomarker Potential
Biomarker candidacy assessment
Genetic Alterations
Mutations, variants, and functional impact
Resistance Landscape
Known resistance mechanisms and mutations
Pathway Context
Pathway membership and functional roles
Interaction Network
Upstream/downstream signaling partners
Key Papers
Most relevant publications, ranked by impact
Contradicted Evidence
Conflicting findings with concordance scores
Evidence Timeline
Publication and discovery chronology
Translational Chain
Basic → Preclinical → Clinical evidence flow
Additional Evidence
Supplementary data from patents, preprints
Related Trials
Possibly relevant trials from semantic matching
See what Synapse knows about your target
Request a demo dossier for any human protein target.